Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Active:	Yes
Cancer Type:	Multiple Myeloma Plasma cell neoplasm	NCT ID:	NCT05317416
Trial Phases:	Phase III	Protocol IDs:	C1071007 (primary) NCI-2023-06350 2021-006052-14 MagnetisMM-7
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Pfizer Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05317416

Summary

The purpose of this study is to evaluate whether elranatamab monotherapy can provide
clinical benefit compared to lenalidomide monotherapy (control) in participants with
newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In
Part 1 and Part 2 of the study, participants in the study will either receive elranatamab
(arm A and C) as an injection under the skin at the study clinic or lenalidomide orally
once daily at home (arm B). Participation in the study will be approximately five years

Objectives

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells
and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.